Catalyst
Slingshot members are tracking this event:
Bristol-Myers Squibb (BMY) Announces Complete Phase 2a Proof-of-Concept Study of BMS-955176 in Treatment of HIV-1
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 23, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bms-955176, Hiv-1, Phase 2a
